Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-i...
Aerpio Pharmaceuticals is a biopharmaceutical c...
ALR Technologies is a medical device company providing remote monitoring and care ...
ALR Technologies is a medical device company pr...
Applied Science Products operates Advanced Plasma Products, Inc., a science and en...
Applied Science Products operates Advanced Plas...
Aptose Biosciences is a clinical-stage biotechnology company developing personaliz...
Aptose Biosciences is a clinical-stage biotechn...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.